Genoptix | GenomeWeb

Genoptix

The evaluation presented at SABCS last week highlighted the importance of considering node-positive and -negative patients, and incorporating clinical information with molecular tests. 

The test, which relies on multiplex IHC and imaging to calculate a PD-1/PD-L1 interaction score, predicted response in melanoma patients better than PD-L1 testing alone.

NEW YORK (GenomeWeb News) – Advanced Cell Diagnostics today said that it has named Genoptix BioPharma Services as its first partner under its CLIA Certified RNAscope Service Provider program.

Trovagene announced last month that it has granted Novartis' diagnostics laboratory, Genoptix, a worldwide, non-exclusive license to incorporate the nucleophosmin protein marker into research and clinical testing services for acute myelogenous leukemia.

NEW YORK (GenomeWeb News) – Trovagene today announced it has granted to Genoptix a non-exclusive license to incorporate nucleophosmin protein (NPM1) into research and clinical testing services for acute myelogenous leukemia.

The acquisition, announced Jan. 24, "complements the Novartis internal capabilities aimed at improving health outcomes by advancing individualized treatment programs," Novartis said in a statement.

Novartis will add the personalized diagnostics lab services to its molecular diagnostics unit.

The license enables Genoptix to use the biomarker analysis technology for cancer diagnostics in the US.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.